Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast cancer.
JA Schneider, CR Divgi, AM Scott, HA Macapinlac, AD Seidman, SJ Goldsmith, SM Larson
J Nucl Med | Published : 1994
UNLABELLED: Our goal was to determine if a healing flare response seen on bone scintigraphy occurs following chemotherapy with Taxol (paclitaxel; Bristol-Myers Squibb Co., Princeton, NJ), a novel antimicrotubule agent for metastatic breast cancer. METHODS: We performed 74 bone scans on 21 females with breast cancer and bone metastases entering a Phase II trial of Taxol chemotherapy with granulocyte colony stimulating factor (G-CSF). All patients had baseline scans within 6 wk prior to therapy, after the second cycle (4-6 wk) of Taxol, and then after 6-12 mo. All bone scans were reviewed by two nuclear medicine physicians, without knowledge of the patients' clinical history. Skeletal radiogra..View full abstract